Lantus must only be used if the solution is clear and colorless with no particles visible. Do not share needles, insulin pens or syringes with others.

Now Merck is ditching the biosimilar Lantus market altogether and shelling out cash to Samsung Bioepis for its costs, too. That leaves Mylan and its partner Biocon as the only major biosimilar ...

In Q3, sales of Lantus were down 9.8% compared with the same period last year, at just under $1.4 billion. Sanofi announced this week plans to cut 20% of jobs in its US diabetes and cardiovascular ...

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect ...

Sales of Lantus were around €6 billion (around $6.5 billion) at their peak but started to decline in 2014 after the first biosimilars were approved in Europe, and as downward pressure on insulin ...

Lantus is Sanofi's top product, though sales have been declining. It's the world's third best-selling medicine, with 2014 sales of $12.4 billion, according to British research firm GlobalData.

Lantus sales reached 3.51 billion euros ($4.70 billion) last year and are expected to peak at $6.5 billion in 2014, according to consensus forecasts from Thomson Reuters Pharma.

Merck's entré further complicates the battle over Lantus, a drug whose sales grew 20% last year to bring in about $7.8 billion for Sanofi. The French drugmaker's patent doesn't expire until 2015 ...

Sanofi-Aventis has responded to swiftly to claims from an analysis of its diabetes drug Lantus which link the drug with an increased risk of cancer. The European Association for the Study of Diabetes ...

The Food and Drug Administration said Wednesday it is reviewing data on the safety of Lantus, a synthetic insulin made by Sanofi-Aventis SA. The move comes after a recent, widely publicized study ...

Sanofi is planning to submit the successor to its blockbuster insulin Lantus (insulin glargine) to regulators for approval next year. U300 is a new, three times more concentrated formulation of ...

Real-world study confirms Basaglar is as safe and effective in type 2 diabetes as Lantus, both formulations of insulin glargine, but the former was cheaper and had better adherence.